Resverlogix Announces Participation at Premier Kidney, Alzheimer’s Disease and Cardiovascular Conferences

CALGARY, Alberta, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) announced today its participation at premier conferences including the American Society of Nephrology (ASN) Kidney Week 2018, Clinical Trials on Alzheimer’s Disease (CTAD) 2018 and the American Heart Association (AHA) Scientific Sessions 2018. Through participation at major conferences and events, the company continues to highlight apabetalone (the first BET inhibitor in a Phase 3 clinical trial for high-risk vascular disease, BETonMACE) and its ability to regulate multiple biological pathways that underlie disease and are known to contribute to cardiovascular, diabetes and neurodegenerative diseases.

The BETonMACE trial is expected to be complete around the end of 2018 with the topline results expected shortly thereafter.

ASN Kidney Week 2018, San Diego, CA

CTAD 2018, Barcelona, Spain

AHA Scientific Sessions 2018, Chicago, IL

Posters will be available on the Company’s website here at the appropriate time.

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile.

Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).

Follow us on Twitter: @Resverlogix_RVX

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to the timing of the BETonMACE trial and the potential role of apabetalone in the treatment of high-risk vascular diseases including CVD, DM and neurodegenerative diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information please contact: Investor Relations Email: ir@resverlogix.com Phone: 403-254-9252 Or visit our website: www.resverlogix.com